Clinical Trials for Premature Coronary Heart Disease: 2 Recruiting

Every trial in this listing is drawn from ClinicalTrials.gov, the federal registry of clinical research operated by the U.S. National Library of Medicine. Each entry on ClinicalTrials.gov is filed by the study sponsor and includes a unique NCT identifier, study design, eligibility criteria, intervention details, sponsor information, sites, and status. TrialFinder reorganizes that public registry data so it is browsable by condition, sponsor, phase, and geography.

Premature Coronary Heart Disease is a relatively narrow research area in this dataset, with 2 trials out of the 7,755 indexed (about 0.03%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites. The most common intervention being tested in Premature Coronary Heart Disease trials is AI-Enabled Stratified Management System (combination_product-class), followed by Usual Post-Discharge Care, VERVE-102. Intervention type matters because it shapes what participation looks like — drug studies typically involve scheduled dosing and bloodwork, device trials involve a procedure or implant, and behavioral studies may only require visits and surveys.

Clinical trials are how new therapies, devices, and procedures get tested before the U.S. Food and Drug Administration decides whether to approve them for general use. Federal law requires most U.S.-based interventional trials to be registered on ClinicalTrials.gov, and many international trials are listed voluntarily. That makes the registry the most comprehensive single window into active medical research for Premature Coronary Heart Disease and other conditions.

Funding for Premature Coronary Heart Disease research skews heavily commercial — roughly 100% of the listed sponsors are pharmaceutical or biotech companies, with academic centers contributing about 0% and government agencies the remaining 0%. Industry-led programs in this area are typically chasing FDA approval for a new molecule or device.

The sponsor matters because it shapes how a trial is designed and run. Industry-sponsored studies are usually tightly protocoled and tied to a regulatory submission. Academic studies often investigate questions a commercial sponsor would not, including comparisons between existing therapies, mechanism-of-disease research, and approaches for patient subgroups too small to be commercially attractive. Government-funded research, including programs run by the National Institutes of Health, frequently focuses on public-health priorities, prevention, and long-term outcomes.

Studies tagged "Not Applicable" are most often observational research, behavioral studies, or device evaluations that do not fit the traditional drug-trial phase framework.

Almost every listed Premature Coronary Heart Disease trial in this dataset is currently recruiting — 2 of 2 studies are actively seeking participants. That high active rate reflects the dataset's focus on enrollment-open studies and means there are real, near-term opportunities for eligible patients to take part.

The development phase tells you what question a trial is asking. Early-phase studies (Phase 1 and Early Phase 1) are about safety and dosing. Phase 2 studies look for an efficacy signal. Phase 3 studies generate the evidence regulators use to decide whether a therapy is approved for general clinical use. Phase 4 studies happen after approval and look at long-term outcomes in real-world settings. Trials labeled "Not Applicable" are typically observational or device studies that do not fit the drug-trial framework.

Premature Coronary Heart Disease is a relatively narrow research area in this dataset, with 2 trials out of the 7,755 indexed (about 0.03%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites.

Across the full TrialFinder dataset of 7,755 indexed studies and 2,541 distinct conditions, the most heavily researched areas tend to cluster around oncology, metabolic disease, and neurology — areas with both large patient populations and active commercial investment. Rare diseases and pediatric conditions usually have smaller absolute trial counts but a higher share of academically and federally funded studies. The Premature Coronary Heart Disease mix above reflects where this condition currently sits on that spectrum.

Premature Coronary Heart Disease trial eligibility varies by study, but Phase 2 work — which is heavily represented in this dataset — usually requires confirmed diagnosis, defined disease activity, and limits on prior therapies. Read each trial's inclusion and exclusion list carefully and bring it to your physician before contacting the study team.

Practical participation considerations include travel to a study site (most trials require in-person visits at a hospital or research center), time commitment (visits often run hours each, with some trials lasting years), and out-of-pocket costs. Trial sponsors typically cover the investigational therapy and study-required tests, but standard-of-care costs may still be billed to the participant or their insurer. A study coordinator can clarify which costs are covered before consent.

Patients and caregivers researching Premature Coronary Heart Disease trials should treat any listing as a starting point for a conversation with their physician. The treating clinician knows the patient's full medical history, current medications, and overall treatment plan, and is best positioned to flag interactions and risks that a registry summary cannot capture. A second medical opinion from a specialist treating Premature Coronary Heart Disease is often valuable before consenting to participate.